- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
MolecularHealth Offers a Reimbursement Calculator
The tool is aimed to provide decision-support to both patients and physicians while considering their reimbursement information.
MolecularHealth has announced an important new component of its TreatmentMAP™ offering in the United States, called MolecularHealth™ RxAssistance. This new service is a value-added benefit for patients and their doctors, providing a level of reimbursement support not previously seen in the molecular diagnostic industry. Unlike reimbursement services offered by other companies that only assess insurance options for the molecular diagnostic test itself, RxAssistance evaluates insurance options for the therapies recommended by its tests.
RxAssistance is designed to help streamline the reimbursement process and provide physicians and patients with support and education about payer reimbursement for treatment options. Each patient’s TreatmentMAP results report and insurance information is reviewed by MolecularHealth’s reimbursement specialist, a Certified Professional Coder®, prior to results being sent to the physician. Off-label or investigational products recommended for treatment are flagged and information is gathered, including the likelihood a payer will reimburse for the suggested treatments and any additional information that will be needed to receive reimbursement, such as a letter of medical necessity.
Read the press release: http://bit.ly/1p0pp5n
Source: MolecularHealth
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Texas Oncology to Roll Out Canopy for ePROs After Head-to-Head Pilot
March 18th 2025Debra Patt, MD, PhD, MBA, executive vice president of Public Policy and Strategy for Texas Oncology, said the practice received positive feedback from nurses and patients during a pilot that concluded in February.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
